GSK PLC closed 25.31% below its 52-week high of £18.24, which the company reached on May 16th.

Rating upgraded from 66 to 73 Tuesday — a welcome improvement, but still shy of the 80 or better score you prefer to see.

Stock futures rebound as key movers like Calix soar on strong Q1 results, while Medpace, Novo Nordisk, and Zion struggle amid mixed guidance and competition.